Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling OutcomesChunaram Choudhary, Hubert Serve, Jesper V. Olsen et al.|Molecular Cell|2009Cited by 315
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Neeraj Saini et al.|Nature Medicine|2023Cited by 226
Germ line<i>DDX41</i>mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Jaroslaw P. Maciejewski, Akifumi Takaori‐Kondo et al.|Blood|2022Cited by 142
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1Maike Janssen, Sascha Dietrich, Christina Schmidt et al.|Blood|2022Cited by 100
The EPHB6 Receptor Tyrosine Kinase Is a Metastasis Suppressor That Is Frequently Silenced by Promoter DNA Hypermethylation in Non–Small Cell Lung CancerJun Yu, Carsten Müller‐Tidow|Clinical Cancer Research|2010Cited by 94